REPARE THERAPEUTICS INC (RPTX)
US7602731025 - Common Stock
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Stay updated with the stocks that are on the move in today's after-hours session.
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund
/CNW/ - Alberta Enterprise Corporation (AEC) announced today that it has invested US$7.5 million into Amplitude Ventures' US$192-million Fund II to give early...
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Amplitude Ventures Closes $263 Million Precision Medicine Venture Fund
/CNW/ - Amplitude Ventures, a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and AI, today announced...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're diving into the biggest pre-market stock movers for Wednesday will a look at all of the latest news happening this morning.
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
RPTX stock results show that Repare Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Repare Therapeutics (NASDAQ:RPTX) just reported results for the first quarter o...
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
Repare Therapeutics Becomes Oversold (RPTX)
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such...
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics GAAP EPS of -$0.67 misses by $0.34, revenue of $13.05M misses by $5.88M (NASDAQ:RPTX)
Repare Therapeutics' Q4 results fall short as their revenue declines due to lower recognized deferred revenue from collaborations with Roche and BMS.
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such...
